SSTR2 and type 2 diabetes mellitus: Protection from hypoglycemia was also reflected in the significantly longer time to hypoglycemia onset in the SSTR2 antagonist-treated group for animals that did develop hypoglycemia (66.1 ± 23.7 vs. 103.1 ± 24.6 min, p < 0.01) and the extent of hypoglycemia (as assessed by AUC analysis for blood glucose <3.9 mmol/L) was significantly greater in the T2D vehicle-treated group compared to the ZT-01-treated group (p = 0.003) (Figure 5B).